For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study…

Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading…

ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost…

Shares of Protagonist Therapeutics plunged more than 60 percent in pre-market trading after the company announced it will discontinue its Phase IIb ulcerative colitis treatment after a review from an…

Allecra Therapeutics released positive top-line data from its Phase II trial of AAI101, an antibiotic against gram-negative bacteria. Source: BioSpace

MorphoSys, a Germany-based biopharmaceutical company, is aiming for a listing on the Nasdaq exchange hoping to secure approximately $150 million. Source: BioSpace

GlaxoSmithKline has decided not to make a play for Pfizer's consumer health business. The decision came one day after another potential suitor walked away from a potential deal. Source: BioSpace

Akebia Therapeutics, a kidney disease company, announced plans to offer and sell about $85 million of its common stock in an underwritten public offering. Source: BioSpace

Healthcare companies are now looking at pharma executives for leadership roles as the landscape of healthcare is dramatically changing. Source: BioSpace

After disappointing mid-stage results and discussions with the FDA, AbbVie will not ask for accelerated approval for its lung cancer drug. Source: BioSpace